Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
CDXS
Codexis IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$236.33M
P/E Ratio
—
EPS
$-0.35
Beta
2.50
52W High
$3.87
52W Low
$0.96
50-Day MA
$2.56
200-Day MA
$2.02
Dividend Yield
—
Profit Margin
-41.00%
Forward P/E
149.25
PEG Ratio
13.53
About Codexis Inc
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
Fundamentals
| Revenue (TTM) | $78.09M |
| Gross Profit (TTM) | $18.61M |
| EBITDA | $-20.55M |
| Operating Margin | -52.70% |
| Return on Equity | -68.90% |
| Return on Assets | -12.50% |
| Revenue/Share (TTM) | $0.88 |
| Book Value | $0.48 |
| Price-to-Book | 5.19 |
| Price-to-Sales (TTM) | 3.03 |
| EV/Revenue | 2.971 |
| EV/EBITDA | -10.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 102.10% |
| Shares Outstanding | $90.90M |
| Float | $73.46M |
| % Insiders | 7.41% |
| % Institutions | 74.40% |
Historical Volatility
HV 10-Day
69.94%
HV 20-Day
66.58%
HV 30-Day
64.50%
HV 60-Day
67.99%
HV Rank
32.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.58 target)
1
Strong Buy4
Buy2
HoldLatest News
Codexis Reports First Quarter 2026 Financial Results
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
GlobeNewsWire5/7/2026Neutral
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research4/30/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026